Tratamiento de la enfermedad de Graves Basedow
Palabras clave:
Hipertiroidismo, bocio, TSH, oftalmopatía, dermopatía, yodo radioactivo, tionamidas, tiroides, Hyperthyroidism, goiter, ophtalmopathy, dermopathy, radioactive iodine, thyonamides, thyroidResumen
RESUMENSe realizó una revisión narrativa rigurosa de la literatura inglesa y en español sobre diferentes aspectos de la Enfermedad de Graves-Basedow e hipertiroidismo. Esta patología –parte de la llamada “enfermedad tiroidea autoinmune”- se produce como consecuencia de la presencia de anticuerpos circulantes que se unen y activan al receptor de tirotropina, desencadenándose generalmente el hipertiroidismo en asociación con un estrés agudo. En este artículo actualizamos tanto el manejo de hipertiroidismo como el de problemas especiales con el que puede estar asociado. La fisiopatología y el diagnóstico de la Enfermedad de Graves-Basedow son motivo de otra publicación.
Palabras clave: Hipertiroidismo, bocio, TSH, oftalmopatía, dermopatía, yodo radioactivo, tionamidas, tiroides.
TREATMENT OF GRAVES-BASEDOW´ S DISEASEABSTRACTA narrative review with systematic methodology of English and Spanish literature on different aspects concerning Graves-Basedow’s disease was carried out. This is one of the pathologies seen in the socalled “autoimmune thyroid disease”, it is associated with presence of thyrotropin-receptor antibodies and is usually triggered by an acute stressful event. We update in this paper the management of hyperthyroidism and of some special associated problems, while the subject of physiopathology and diagnosis of Graves-Basedow is a matter of discussion in another publication.
Key words: Hyperthyroidism, goiter, TSH, ophtalmopathy, dermopathy, radioactive iodine, thyonamides, thyroid.
Biografía del autor/a
Hernando Vargas-Uricoechea, Facultad Ciencias de la Salud, Universidad del Cauca, Popayán.
Carlos Hernán Sierra-Torres, Facultad Ciencias de la Salud, Universidad del Cauca, Popayán.
Ivonne Alejandra Meza-Cabrera, Facultad Ciencias de la Salud, Universidad del Cauca, Popayán.
Referencias bibliográficas
REFERENCIAS
Cooper DS. Antithyroid Drugs. N Engl J Med. 2005; 352:905-917.
Nygaard B. Hyperthyroidism (primary). ClinEvid (Online). 2010 Jul 19; 2010. pii: 0611.
Abraham P, Acharya S. Current and emerging treatment options for Graves’ Hyperthyroidism. Therap Clin Risk Manag. 2010; 6:29-40.
Bartalena L, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E. An update on the pharmacological management of hyperthyroidism due to Graves’ disease. Expert Opin Pharmacother. 2005; 6:851-861.
Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003420. DOI: 10.1002/14651858.CD003420.pub4.
Iagaru A, McDougall IR. Treatment of Thyrotoxicosis. J Nucl Med. 2007; 48:379-389.
Andre`s E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Brit J Haematol. 2010; 150:3-8.
Watanabe N,Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y,Mukasa K, Ito K, Ito K. Antithyroid Drug-Induced Hematopoietic Damage: A Retrospective Cohort Study of Agranulocytosis and Pancytopenia Involving 50,385 Patients with Graves’ Disease. J Clin Endocrinol Metab. 2012; 97:E49-E53.
Sun MT, Tsai CH, Shih KC. Antithyroid drug-induced agranulocytosis. J Chin Med Assoc. 2009; 72:438-441.
Nwatsock JF, Taieb D, Tessonnier L, Mancini J, Dong- A-Zok F, Mundler O. Radioiodine thyroid ablation in Grave’s Hyperthyroidism: Merits and pitfalls. World J Nucl Med. 2012; 11:7-11.
Ross DS. Radioiodine Therapy for Hyperthyroidism. N Engl J Med 2011; 364:542-550.
Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf). 1995; 43:325-329.
Van Isselt JW, de Klerk JMH, Lips CJM. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging. 2007; 34:1883-1884.
Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study. Eur J Nucl Med 2001; 28:1489-1495.
Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm. 2005; 20:218-223.
Oszukowska L, Knapska-Kucharska M, Lewiski A. Effects of drugs on the efficacy of radioiodine (131I) therapy in hyperthyroid patients. Arch Med Sci. 2010; 6(1):4-10.
deRooij A, Vandenbroucke JP, Smit JWA, Stokkel MPM, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. European Journal of Endocrinology. 2009; 161:771-777.
Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012; 33(6):920-980.
Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased Cancer Incidence After Radioiodine Treatment for Hyperthyroidism.CANCER. 2007;109(10):1972-1979.
Angusti T, Codegone A, Pellerito R, Favero A. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. J Nucl Med.2000; 41:1006-1009.
Thyroid Function after Subtotal Thyroidectomy in Patients with Graves’ Hyperthyroidism. E. J. Limonard EJ, Bisschop PH, Fliers E, Nieveen van Dijkum EJ. Scient World J. Volume 2012, Article ID 548796, doi:10.1100/2012/548796.
Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: A meta-analysis. J Surg Res. 2000; 90:161-165.
Kaplan EL, Angelos P. Surgery of the Thyroid Gland. Thyroid Disease Manager. Available at: www.thyroidmanager. org/Chapter21/21-frame.htm.
Stalberg P, Svensson A, Hessman O, Akerstrom GA, Hellman P, “Surgical treatment of Graves’ disease: evidence based approach,” World J Surg.2008;32(7):1269-1277.
Sugino K, Ito K, Nagahama M, Kitagawa W, ShibuyaH, Ito K. “Surgical management of Graves’ disease— 10-year prospective trial at a single institution,” Endocrine Journal. 2008; 55(1):161-167.
Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH, “Should total thyroidectomy become the preferred procedure for surgical management of Graves’ Disease?” Thyroid.2005; 15(6):569-574.
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists”. Thyroid.2011; 21(6):593-646.
Genovese BM, Noureldine SI, Gleeson EM, TufanoRP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2012 DOI 10.1245/ s10434-012-2606-x.
Marx H, Amin P, Lazarus JH. PREGNANCY PLUS. Hyperthyroidism and pregnancy. Brit Med J. 2008; 336: 663-667.
Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy.
Europ J Endocrinol. 2009;160:1-8.
Abalovich M, Amino N, Barbour LA, Cobin RH, DeGroot LJ, Glinoer D, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab.2007; 92(8) Suppl: S1-47.
Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab.2007; 3:470-478.
Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, et al. Management of Graves’ Disease during Pregnancy: The Key Role of Fetal Thyroid Gland Monitoring. J Clin Endocrinol Metab.2005; 90:6093-6098.
Bahn RS. Graves’ ophthalmopathy. New Engl J Med.2010; 362:726-738.
Soeters MR, van Zeijl CJJ, BoelenA, Kloos R, Saeed P, Vriesendorp TM, Mourits P. Optimal management of Graves’s orbitopathy: a multidisciplinary approach. Netherl J Med. 2011; 69(7/8):302-308.
Regensburg NI, Wiersinga WM, Berendschot TT, Potgieser P, Mourits MP. Do subtypes of Graves’ orbitopathy exist? Ophthalmol. 2011; 118(1):191-196.
Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A. Graves’ ophthalmopathy: a review of immunogenetics. Curr Genomics. 2011; 12(8):564-575.
Maheshwari R, Weis E. Thyroid associated orbitopathy. Indian J Ophthalmol. 2012; 60(2):87-93.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and perspectives. Endocr Rev. 2000; 21:168-199.
Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):371-379.
Hegedüs L, Bonnema SJ, Smith TJ, Brix TH. Treating the thyroid in the presence of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012 26(3):313-324.
Marcocci C, Marinò M. Treatment of mild, moderateto- severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):325-337.
Müller-Forell W, Kahaly GJ. Neuroimaging of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):259-271.
Kirsch E, Hammer B, von Arx G. Graves’ orbitopathy: current imaging procedures.Swiss Med Wkly. 2009; 139(43/44):618-623.
Yang M, PerrosP. Management plan and delivery of care in Graves’ ophthalmopathy patients. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):303-311.
Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012 Jun; 26(3):229-248.
Rajendram R, Bunce C, Lee RW, Morley AM. Orbital radiotherapy for adult thyroid eye disease. Cochrane Database Syst Rev. 2012 Jul 11; 7:CD007114. doi: 10.1002/14651858.CD007114.pub2.
Sabih DE, Inayatullah M. Managing thyroid dysfunction in selected special situations. Thyroid Res. 2013; 6:2 doi: 10.1186/1756-6614-6-2.
Li H, Want T. The autoimmunity in Graves’disease. Front Biosci.2013; 1(18):782-787.
Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore) 1994; 73:1-7.
Fatourechi V. Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab. 2012; 26(4):553-565.
Fatourechi V. options. Am J Clin Dermatol. 2005; 6(5):295-309.
Reddy SV, Gupta SK, Jain M. Dermopathy of Graves’ disease: Clinico-pathological correlation. Indian Med J 2012; 16(3):460-462.
Vannucchi G, Campi I, Covelli D, Forzenigo L, Beck- Peccoz P, Salvi M. Treatment of pretibial myxedema with dexamethasone injected subcutaneously by mesotherapy needles. Thyroid. 2013 Feb 11. [Epubahead of print].
Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (Pretibial myxedema): Long-term outcome. J Clin Endocrinol Metab. 2002; 87:438-446.
Vargas-Uricoechea H, Sierra-Torres CH, Meza-Cabrera I: Enfermedad de Graves Basedow, Fisiopatología y Diagnóstico. Medicina 2013; 35(1): 41-66 .
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Copyright
ANM de Colombia
Los autores deben declarar revisión, validación y aprobación para publicación del manuscrito, además de la cesión de los derechos patrimoniales de publicación, mediante un documento que debe ser enviado antes de la aparición del escrito. Puede solicitar el formato a través del correo revistamedicina@anmdecolombia.org.co o descargarlo directamente Documento Garantías y cesión de derechos.docx
Copyright
ANM de Colombia
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent.
